• 1
    Kumar V, Jagannathan NR, Thulkar S, Kumar R. Prebiopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer. Int. J. Urol. 2012; 19: 602613.
  • 2
    Kumar V, Jagannathan NR, Kumar R et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml. NMR Biomed. 2007; 20: 1120.
  • 3
    Kumar R, Nayyar R, Kumar V et al. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/mL: a follow-up study. Urology 2008; 72: 859863.
  • 4
    Giusti S, Caramella D, Fruzzetti E, Lazzereschi M, Tognetti A, Bartolozzi C. Peripheral zone prostate cancer. Pre-treatment evaluation with MR and 3D 1H MR spectroscopic imaging: correlation with pathologic findings. Abdom. Imaging 2010; 35: 757763.
  • 5
    Vilanova JC, Barceló-Vidal C, Comet J et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer. AJR Am. J. Roentgenol. 2011; 196: W715722.
  • 6
    Haffner J, Lemaitre L, Puech P et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011; 108 (8 Pt 2): E171178.